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Introduction {#sec1}
============

Organisms undergo age-dependent alterations in body size and function as they grow into adults. One of the mechanisms regulating this process is an age-dependent transition in gene expression that is regulated at the transcriptional and post-transcriptional levels. Transcription is a process of mRNA synthesis controlled quantitatively by factors such as RNA polymerases, transcription factors, and chromatin modifiers. Transcription is also controlled qualitatively by the use of alternative transcription start sites and alternative polyadenylation. The post-transcriptional processing includes alternative splicing (AS), (de)stabilization, RNA modifications such as RNA methylation ([@bib56]), RNA editing, interaction with RNA-binding protein (RBP, [@bib2]) and microRNA, transportation, and compartmentalization.

AS increases transcript diversity. Following the discovery of splicing ([@bib5], [@bib11]), AS was identified as a system that generated multiple variant mRNAs from one gene ([@bib1], [@bib16]). This process enables a limited number of genes to generate more molecules. AS thus expands the proteome ([@bib40]) and is relevant to evolution ([@bib4]). AS occurs in tissue-specific patterns ([@bib7], [@bib17]) and cell-type-specific patterns (e.g., embryonic stem cells \[[@bib22], [@bib43]\]), suggesting its role in differentiating cellular contexts. AS has broad biological implications in synapse formation ([@bib49]), sex determination ([@bib3]), the epithelial-mesenchymal transition ([@bib54]), etc. AS is also implicated in pathogenesis ([@bib12], [@bib48]) and cancer ([@bib51]). Despite the multifaceted nature of AS, its age dependency is not well understood. Here, we investigate age-dependent alternative splicing (ADAS) in the context of postnatal organ growth in mice.

The postnatal growth phase is a process in which an animal incorporates nutrition for anabolism, thus growing in size. In addition, the functions of the organs mature during the process of growing into an adult. For example, the brain undergoes striking functional enhancement via functional plasticity ([@bib23]). Thus, juvenile animals possess distinct physiological characteristics, which we call "juvenile properties" ([@bib26], [@bib47]). Despite its particular physiological traits, the juvenile phase has not been studied as rigorously as the fetal development or adult phases. Thus, to explore these juvenile properties, we previously performed a comprehensive transcriptome analysis in mice of different ages and identified juvenility-associated genes (JAGs, [@bib26]) and juvenility-associated long noncoding RNAs (JALNCs, [@bib47]) as molecular building blocks of juvenile properties. These analyses revealed that the juvenile phase is characterized by a specific gene expression profile (hereafter, juvenile transcriptome) quite distinct from that of adults.

Our analyses of the juvenile transcriptome identified AS as an important mechanism regulating juvenile properties ([@bib26]), although the details remained unaddressed. Here, we show that juveniles undergo global AS in an age-dependent manner that shapes the juvenile transcriptome. AS is the differential removal of introns from pre-mRNA and is observed in 92%--94% of multi-exon genes ([@bib42], [@bib53]). Splicing is carried out in spliceosomes that consist of five small nuclear ribonucleoprotein particles (snRNPs), U1, U2, U4/U6, and U5; these snRNPs are the major components of the spliceosome, and numerous auxiliary proteins are also present ([@bib9]). Spliceosome assembly is a highly dynamic process that starts with the binding of SR proteins to exonic splicing enhancer (ESE); these proteins stabilize the interaction of the U1 snRNP to the 5′ splicing site (5′ ss) of the intron via base pairing with snRNA1 ([@bib35]). The SR proteins also recruit the U2AF complex and U2 snRNP to the 3′ ss ([@bib9], [@bib40]). Further incorporation of the U4/U6--U5 tri-snRNP leads to the formation of a complex that contains all subunits, followed by extensive conformational changes, resulting in the formation of the catalytically active spliceosome.

The Srsf7 splicing factor belongs to the SR protein family, which is encoded by nine genes in humans: *SRSF1* (chr17), *SRSF2* (chr17), *SRSF3* (chr6), *SRSF4* (chr1), *SRSF5* (chr14), *SRSF6* (chr20), *SRSF7* (chr2), *SRSF9* (chr12), *SRSF11* (chr1, [@bib45]). The SR splicing factors possess an N-terminal RNA-binding domain (RBD) and a C-terminal RS domain that is enriched with arginine-serine dipeptides. The RS domain mediates protein-protein interactions that are required for spliceosome assembly ([@bib32], [@bib55]). Srsf7 additionally possesses a zinc-affinity domain between the RBD and the RS domain ([@bib27]). It was also reported that a binding location relative to the 5′ ss affects the splicing regulation function of Srsf7 ([@bib18]). Srsf7 transports herpes simplex virus 1 mRNAs ([@bib19]) and is involved in processing HIV-1 mRNA ([@bib50]), but the biological roles of Srsf7 remain largely unknown.

Here, we describe ADAS in postnatally growing mouse organs as a model and investigate a role for Srsf7 in the regulation of ADAS. Our analysis provides a landscape for ADAS and clarifies a role for Srsf7 in ADAS and the establishment of the juvenile transcriptome.

Results {#sec2}
=======

Age-Dependent Alternative Splicing in Growing Organ Transcriptomes {#sec2.1}
------------------------------------------------------------------

To comprehensively address ADAS, we performed a transcriptome analysis with mouse organs and analyzed AS events in a transcriptome-wide manner. We performed RNA sequencing (RNA-seq) analysis with the cerebral cortex (CC) of C57BL/6N mice in the juvenile and adult phases. We utilized postnatal day 1 (P1) and P14 as juvenile phases and P56 as an adult phase. We combined the data from the CC with our previously publicized dataset of cardiomyocytes (CMs) and hepatocytes (Heps) from mice of juvenile (P1 and P7) and adult (P56) phases ([@bib26]). We investigated AS events among the different ages using the mixture-of-isoforms (MISO) model ([@bib29]) and comprehensively identified AS events that occurred in a phase-specific manner as ADAS events ([Figure 1](#fig1){ref-type="fig"}A). This analysis identified numerous ADAS events, as examples, in *Tpm2*, *Ndrg2*, and *Fn1* ([Figure 1](#fig1){ref-type="fig"}B). *Tpm2* underwent exon skipping in which an exon was included in a juvenile-specific manner (juvenile-exon inclusion). In contrast, *Ndrg2* underwent exon skipping in an adult-specific manner. *Fn1* underwent multiple AS events that consisted of mutually exclusive exon usage, with distinct juvenile and adult exon inclusions.Figure 1Comprehensive Identification of Age-Dependent Alternative Splicing (ADAS) in Organ Growth(A) Schematic of the age-dependent alternative splicing (ADAS) analysis in this study. MISO, mixture of isoforms.(B) Representative examples of ADAS events in postnatal cardiomyocytes. Numbers shown to the left of the read patterns indicate FPKM values. Exon information was shown below.(C) Total number of ADAS events in cerebral cortex (CC), cardiomyocytes (CMs), and hepatocytes (Heps). The alternative splicing (AS) events were analyzed by MISO, and AS events with Bayes factors \> 10^1/2^ were counted.(D) Numbers of each AS pattern in postnatally growing mouse organs.(E) Frequency of juvenile- or adult-enriched specific exon inclusions. The frequency was compared between P1 and P56 or between P7 (CMs and Heps)/P14 (CC) and P56.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

The analysis of AS events identified 1,264, 408 and 371 total ADAS events in the CC, CMs, and Heps, respectively ([Figure 1](#fig1){ref-type="fig"}C). Among the five types of ADAS (exon skipping, intron retention, mutually exclusive exons, 5′ or 3′ alternative ss), exon skipping was the most frequent ([Figure 1](#fig1){ref-type="fig"}D). There were two types of exon skipping: juvenile- and adult-enriched exon inclusion. Adult-enriched exon inclusion was more frequent (533 events) than juvenile-enriched exon inclusion (238 events, [Figure 1](#fig1){ref-type="fig"}E). To determine the biological relevance of ADAS, a Gene Ontology (GO) analysis was performed for the differentially spliced genes at the juvenile and adult phases ("ADAS-target genes"). The ADAS-target genes were significantly associated with "nervous system development" and "axonogenesis" in the CC, "cell-cell adhesion" and "muscle contraction" in CMs, and "mitochondrial fission" and "extracellular exosome" in Heps. These results indicate that the ADAS-target genes are engaged in the biologically relevant functions ([Figure S1](#mmc1){ref-type="supplementary-material"}). Thus, we comprehensively determined the ADAS events in postnatal growth and identified the juvenile-specific splicing isoforms.

Juvenile Expression of *Srsf7* {#sec2.2}
------------------------------

We next explored how the ADAS events were regulated. We hypothesized that juvenile-specific AS was mediated by juvenile-specifically expressed splicing factor(s) (SFs), so we tested whether SFs were expressed in a juvenile-specific manner. We investigated 59 SFs that were curated manually ([@bib21]). Unexpectedly, most of the SF genes were expressed more highly in juvenile tissues throughout the CC, CMs, and Heps, suggesting their functional relevance in juveniles ([Figure S2](#mmc1){ref-type="supplementary-material"}). Among the juvenile-expressed SFs, we narrowed down the candidate genes for functional analyses by choosing those with robust and at least 2-fold higher expression than in adult in the three tissues. Among the seven genes, *Ybx1*, *hnRNP A0*, *hnRNP A1*, *hnRNP DL*, *Sfpq*, *Srsf2*, and *Srsf7*, we focused on *Srsf7* with a relatively unknown biological function. We will analyze the remaining six genes in a future work. *Srsf7* exhibited prominent juvenile-specific expression with high expression levels in juveniles in all three cell types ([Figure 2](#fig2){ref-type="fig"}A). This juvenile-predominant expression was validated with quantitative PCR ([Figure 2](#fig2){ref-type="fig"}B). Our previous analysis revealed that Srsf7 was suppressed in cellular juvenescence loss induced by depletion of the JALNC *Gm14230* ([@bib47]). Immunocytochemistry revealed that Srsf7 was localized predominantly to the nucleoplasm in Neuro2a mouse neuroblastoma cells at a lower cell density ([Figures 2](#fig2){ref-type="fig"}C and 2D). At a higher cell density, Srsf7 expression was suppressed ([Figures 2](#fig2){ref-type="fig"}C and 2D). This cell-density-dependent expression suggests a role for Srsf7 in the regulation of cellular growth.Figure 2*Srsf7* Is Expressed in Juvenile Organs and Juvenescent Cells(A) IGV views of *Srsf7* expression in the cerebral cortex (CC), cardiomyocytes (CMs), and hepatocytes (Heps) at juvenile phase postnatal day 1 (P1), P7 (CMs and Heps), or P14 (CC) and adult phase P56. Numbers next to the read patterns (0, 100, and 600) indicate FPKM values.(B) qPCR analysis of *Srsf7* mRNA expression in CC, CMs, and Heps. Data were normalized to *Polr2a*.(C) Immunofluorescent analysis of Srsf7 and Vimentin in Neuro2a cells at low and high densities. Scale bar, 50 μm.(D) Frequency of Srsf7-expressing cells among total cells. ∗∗∗ p \< 0.001. *n* = 266 and 243 cells. Data are the means ± standard deviations from three independent experiments.(E) Staining of senescence-associated β-galactosidase (SA-β-gal) activity in cells treated with zeocin at 80 μg/mL for 96 h. Scale bar, 50 μm.(F) Frequency of cells positive for SA-β-gal staining. ∗∗∗ p \< 0.001. *n* = 365 and 158 cells. Data are the means ± standard deviations from three independent experiments.(G) Immunofluorescent analysis of Srsf7 in Neuro2a cells with or without zeocin treatment. Scale bar, 50 μm.(H) Frequency of Srsf7-expressing cells among total cells. ∗∗∗ p \< 0.001. *n* = 465 and 291 cells. Data are the means ± standard deviations from three independent experiments.(I) Western blot analysis with Neuro2a cells treated with zeocin. The senescence marker proteins γH2ax and p16 were increased in zeocin-treated cells. Actb was used as a loading control.∗p \< 0.05 and ∗∗∗p \< 0.001, Student\'s t test. Data are represented as the means ± standard deviations. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

We next asked whether Srsf7 expression depends on cellular juvenescence. Zeocin, a genotoxic agent, induces loss of cellular juvenescence in NIH3T3 cells ([@bib47]). We applied this method to Neuro2a cells and observed highly efficient induction of cellular senescence, as indicated by senescence-associated β-galactosidase (SA-β-gal) activity and extension of the cytoplasm ([@bib44]) ([Figures 2](#fig2){ref-type="fig"}E and 2F). Srsf7 expression was significantly suppressed in the senescent cells ([Figures 2](#fig2){ref-type="fig"}G and 2H), and this result was corroborated by western blot analysis ([Figures 2](#fig2){ref-type="fig"}I and [S2](#mmc1){ref-type="supplementary-material"}B). We also analyzed the juvenescence-dependent expression of Srsf7 in another model for cellular senescence. Cellular senescence can be induced by oncogenic genes such as *Ras* ([@bib44]), *BRAF* ([@bib52]), *Akt* ([@bib10]), and *E2F* ([@bib15]). The forced expression of *RasV12* by doxycycline-inducible manner provoked cellular senescence, which was evidenced by changes in cell morphology and impaired cell growth ([Figures S2](#mmc1){ref-type="supplementary-material"}C). The *RasV12*-induced cellular senescence was accompanied by suppression of Srsf7 and enhancement of proteins associated with cellular senescence ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2E). Thus, *Srsf7* is more highly expressed in juvenile organs and juvenescent cells.

Depletion of *Srsf7* Causes Loss of Cellular Juvenescence and Metabolic Dysfunction {#sec2.3}
-----------------------------------------------------------------------------------

To study the role of *Srsf7* in cellular juvenescence, we tested the influence of *Srsf7* depletion in Neuro2a cells. siRNA-mediated knockdown of *Srsf7* ([Figure 3](#fig3){ref-type="fig"}A) significantly suppressed cell growth ([Figures 3](#fig3){ref-type="fig"}B and 3C), indicating that *Srsf7* was essential for cell growth. The *Srsf7*-depleted cells were refractory to retinoic acid-induced neural differentiation, indicating that the *Srsf7*-depleted cells lost their ability to differentiate ([Figure 3](#fig3){ref-type="fig"}D). The earlier findings that Srsf7 was expressed in juvenile cells prompted us to test whether Srsf7 is required for cellular juvenescence. Srsf7 knockdown led to a profound increase in positive staining in an SA-β-gal assay ([Figures 3](#fig3){ref-type="fig"}E and 3F) and the expression of the senescence-associated proteins p16, p27, and γH2ax ([Figures 3](#fig3){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}A). These results indicate that Srsf7 is essential for cellular juvenescence. We next assessed a role for Srsf7 in counteracting the cellular senescence. The Neuro2a-RasV12 cells were transfected with *Srsf7* or control empty plasmid, followed by doxycycline treatment to induce the cellular senescence. The forced expression of *Srsf7* suppressed the morphological changes of the cells, in comparison with the control plasmid-transfected cells ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C).Figure 3*Srsf7* Is Essential for Cellular Juvenescence(A) *Srsf7* knockdown efficiency was analyzed by qPCR of *Srsf7* in Neuro2a cells 48 h after transfection with control siRNA or *Srsf7* siRNA. Data were normalized to *Actb*.(B) Appearance of Neuro2a cells 72 h after transfection with control siRNA or *Srsf7* siRNA. Scale bar, 100 μm.(C) Number of cells per field 72 h after transfection with control siRNA or *Srsf7* siRNA.(D) Appearance of Neuro2a cells treated with 20 μM retinoic acid for 48 h to induce neural differentiation. *Srsf7*-depleted cells were refractory to differentiation induction. Scale bar, 100 μm.(E) Staining of senescence-associated β-galactosidase (SA-β-gal) activity in Neuro2a cells 72 h after transfection with control siRNA or *Srsf7* siRNA. Scale bar, 100 μm.(F) Frequency of cells positive for SA-β-gal staining among total cells. ∗∗∗ p \< 0.001. *n* = 147 and 184 cells. Data are the means ± standard deviations from three independent experiments.(G) Western blot analysis with Neuro2 cells 72 h after transfection of control siRNA or *Srsf7* siRNA. The senescence marker proteins p16, p27, and γH2ax were increased in *Srsf7*-depleted cells. Tubulin was used as a loading control.(H--K) Analysis of cell metabolism with a flux analyzer in Neuro2a cells 48 h after transfection of control siRNA or *Srsf7* siRNA. (H) Oxygen consumption rate (OCR) and (I) extracellular acidification rate (ECAR) were measured at baseline and under stress conditions in which cells were treated with oligomycin and FCCP. (J) OCR to ECAR ratio at the baseline and stress conditions. (K) Energy phenotype profile of the cells transfected with control siRNA or *Srsf7* siRNA.∗ p \< 0.05, ∗∗ p \< 0.01, and ∗∗∗ p \< 0.001, Student\'s t test. Data are represented as the means ± standard deviations. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

To analyze the mechanism of growth regulation by *Srsf7*, we assessed the expression of metabolism-associated proteins. *Srsf7* depletion caused decreased phosphorylation of the ribosomal protein S6 (Ser240/244), suggesting impaired protein synthesis ([Figure 3](#fig3){ref-type="fig"}G). Additionally, *Srsf7* knockdown induced form II of Lc3, a hallmark of autophagy, suggesting that *Srsf7* depletion caused energy starvation. The findings implied that Srsf7 is required for cell anabolism. To assess the metabolic function of Srsf7, we measured cellular metabolism with a flux analyzer and revealed that *Srsf7* depletion led to a decreased oxygen consumption rate (OCR, [Figure 3](#fig3){ref-type="fig"}H) with minor effects on extracellular acidification rate (ECAR [Figure 3](#fig3){ref-type="fig"}I), suggesting that mitochondrial function was impaired. Analysis of the OCR to ECAR ratio showed *Srsf7* depletion compromised oxidative phosphorylation ([Figure 3](#fig3){ref-type="fig"}J), causing a shift to glycolysis ([Figure 3](#fig3){ref-type="fig"}K). We next addressed how the *Srsf7* depletion led to the metabolic shift toward the compromised oxidative phosphorylation. We first assessed mitochondrial quantity by measuring the amount of mitochondrial genome DNA. This analysis did not show a significant change in the mitochondrial quantity upon *Srsf7* depletion ([Figure S3](#mmc1){ref-type="supplementary-material"}D). The expression of mitochondrial protein Cox1 did not alter apparently ([Figure 3](#fig3){ref-type="fig"}G). To investigate the potential mechanism behind the metabolic shift, we established *Srsf7*-knockout (KO) Neuro2a cell lines via CRISPR technology and performed transcriptome analysis. The RNA-seq analysis revealed upregulation of *pyruvate dehydrogenase kinase* (*Pdk1*) and *Pdk2* in the *Srsf7*-KO cells. These findings were validated via qPCR ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Pdk proteins direct the metabolic flow from the oxidative phosphorylation to glycolysis ([@bib30], [@bib31], [@bib33]). The enhancement of Pdk1 was also observed at the protein level in the cells depleted for *Srsf7* ([Figure 3](#fig3){ref-type="fig"}G). Together, *Srsf7* depletion causes the glycolysis-predominant state that is accompanied with the upregulation of Pdk. Thus, *Srsf7* is essential for cellular juvenescence and mediates cellular anabolism.

*Srsf7* Regulates Growth and JAGs in Mice {#sec2.4}
-----------------------------------------

To assess the role of Srsf7 in ADAS in mice, we sought to analyze *Srsf7*-knockout (KO) mice. Using CRISPR-Cas9 genome editing ([@bib13], [@bib24], [@bib37]), we designed a guide RNA that introduced a double-strand break in the proximal region downstream of the initiating codon in *Srsf7* ([Figure S4](#mmc1){ref-type="supplementary-material"}A). This break resulted in an indel that caused a frameshift (fs) mutation ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Analysis of newborns revealed that none had homozygous mutations, implying that the null mutation caused embryonic lethality. Analysis of fetuses at embryonic day 7.5 (E7.5) revealed that 18 fetuses (27.6%) were wild-type (WT, *Srsf7*^WT/WT^), 30 (46.1%) were heterozygous mutants (*Srsf7*^WT/fs^), and 17 (26.1%) were absorbed embryos, hampering the determination of a genotype ([Figure S4](#mmc1){ref-type="supplementary-material"}C). The absence of a viable homozygous mutant at E7.5 suggested early embryonic lethality. KO of *Srsf3* (also known as SRp20), a gene that encodes the SF with the closest similarity to Srsf7 ([@bib6], [@bib8]), causes developmental failure at the blastocyst stage ([@bib28]). We therefore analyzed whether *Srsf7*-null embryos had defects at the blastocyst stage. *In vitro* fertilization was performed with *Srsf7* heterozygous mutant sperm and ova to analyze development into morulae and blastocysts. *Srsf7*-homozygous KO embryos (*Srsf7*^fs/fs^) successfully developed into blastocysts, clarifying that the embryonic lethality of *Srsf7*-KO mice occurred after the blastocyst stage and during the implantation stage ([Figures S4](#mmc1){ref-type="supplementary-material"}D--S4F). Taken together, these results show that *Srsf7* is indispensable for the implantation stage of mouse development.

The embryonic lethality hampered the analysis of homozygous KO mice. Heterozygous *Srsf7*-KO mice were viable and fertile, but they exhibited impaired body growth. Both male and female *Srsf7*^WT/fs^ mice exhibited lower body weight than the WT controls ([Figures 4](#fig4){ref-type="fig"}A and 4B), indicating that *Srsf7* is necessary for body growth in mice. The significant difference of body weight was observed also in the neonatal phase ([Figure S5](#mmc1){ref-type="supplementary-material"}A). To gain an insight into a role for *Srsf7* in the protein synthesis *in vivo*, we investigated the expression of proteins associated with the activity of the protein synthesis. The expression of phosphorylated S6 and phosphorylated 4E-BP1 was suppressed in the *Srsf7* mutant tissues ([Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C). These findings implied that *Srsf7* might play a role in the regulation of protein synthesis also *in vivo*. To assess the machinery underlying the growth impairment of *Srsf7* mutant mice, we compared the gene expression profiles of WT and *Srsf7* mutants via RNA-seq ([Figure 4](#fig4){ref-type="fig"}C).Figure 4*Srsf7* Regulates Growth and JAGs in Mice(A) The body weights of WT and *Srsf7*-heterozygous mutant mice (numbers of mice analyzed: WT male, 12; mutant male, 19; WT female, 17; mutant female, 14).(B) Appearances of WT and *Srsf7* mutant mice at age 2 weeks.(C) A schematic describing the RNA-seq analysis with CC, CMs, and Heps isolated from WT and *Srsf7* mutant mice. Two Srsf7 mutant mice and one WT littermate control were subjected to the RNA-seq analysis.(D) Heatmap analysis of the RNA-seq results in CC, CMs, and Heps of WT and *Srsf7* mutant mice. The cluster of genes with a tendency to be downregulated in the three organs is magnified to the right. A partial list of JAGs and translation-associated genes included in the cluster is shown.(E) Gene Ontology (GO) analysis of the *Srsf7* mutant-suppressed cluster. The biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways significantly associated with the cluster are shown.(F) Frequencies of juvenility-associated genes (JAGs) and constitutively expressed genes among the *Srsf7*^WT/fs^-suppressed genes. The *Srsf7* mutation affects JAGs more strongly than constitutively expressed genes.∗ p \< 0.05 and ∗∗∗ p \< 0.001, Student\'s t test. Data are represented as the means ± standard deviations. See also [Figures S4--S6](#mmc1){ref-type="supplementary-material"}.

Heatmap analysis revealed that a subset of genes (1,716 genes) was suppressed by the *Srsf7* mutation throughout the CC, CMs, and Heps ([Figure 4](#fig4){ref-type="fig"}D). The subset included numerous JAGs and translation-associated genes ([Figure 4](#fig4){ref-type="fig"}D). The GO analysis revealed that this gene subset was associated with "translation" (p \< 10^−33^) and "ribosome" (p \< 10^−39^) ([Figure 4](#fig4){ref-type="fig"}E). These findings suggested that translation was dysregulated in the *Srsf7* mutant mice. Additionally, the *Srsf7* mutation showed a significantly more profound effect on the JAGs than on constitutively expressed genes, demonstrating that Srsf7 is indispensable for the expression of JAGs ([Figure 4](#fig4){ref-type="fig"}F). Among the JAGs, the expression of *Igf2* was suppressed significantly in CMs and Heps ([Figure S5](#mmc1){ref-type="supplementary-material"}D). *Igf2* encodes a peptide that functions as a potent enhancer of body growth ([@bib14], [@bib46]). The Igf2 suppression was observed also at the protein level in *Srsf7* mutant hearts and livers ([Figure S5](#mmc1){ref-type="supplementary-material"}E). We also addressed physiological consequences of the aberrant ADAS in the *Srsf7* mutant mice. The GO analysis in the *Srsf7* mutant CC revealed that genes associated with myelination were affected significantly ([Figures S6](#mmc1){ref-type="supplementary-material"}A), revealing the downregulation of myelin sheath-associated genes ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Immunostaining of myelin basic protein (MBP) revealed poorer myelination in the *Srsf7* mutant compared with WT ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D), whereas the neuronal formation was unaffected ([Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F). Thus, the *Srsf7* mutant mice showed the slight impairment of myelination in the CC. Together, the *Srsf7* mutation causes physiological deteriorations in the body growth and myelination that is accompanied by compromised expression of genes associated with translation and JAGs in mice.

*Srsf7* Mediates ADAS {#sec2.5}
---------------------

We next evaluated ADAS in the *Srsf7* mutant mice. MISO analysis revealed significantly (Bayes factor \> 10^1/2^) and recurrently altered AS events in the *Srsf7* mutant mice ([Figure 5](#fig5){ref-type="fig"}A). The cutoff we used for determining true AS events almost completely excluded background or "noise" AS events, as shown by the fact that comparisons among WT mice showed few AS events ("Background AS events" in [Figure 5](#fig5){ref-type="fig"}A). We performed GO analysis to predict the biological functions associated with the mis-spliced genes, and the results showed that, in addition to the expected "alternative splicing" (10^−153^) ([Figure 5](#fig5){ref-type="fig"}B), functions such as "phosphoprotein" (10^−110^) and "acetylation" (10^−46^) were highly significantly enriched. These findings indicate that *Srsf7* exerts its influence through these enriched functions. We next asked whether Srsf7 mediated the ADAS that was observed earlier in this study. We investigated an overlap between the ADAS-target genes and the genes undergoing Srsf7-dependent AS. Overlaps of 33.1%, 41.8%, and 43.5% were observed between the ADAS-target genes and Srsf7-spliced genes in the CC, CMs, and Heps with statistical significance of 2 × 10^−102^, 3 × 10^−91^, and 8 × 10^−71^, respectively ([Figure 5](#fig5){ref-type="fig"}C). These observations indicate that Srsf7 mediates a considerable portion of ADAS, thus establishing a role for Srsf7 in the age-dependent transition of the transcriptome.Figure 5*Srsf7* Mediates ADAS in Mice(A) Number of AS events detected in *Srsf7* mutant mice in comparison with WT mice (right half, "Mis-splicing events in *Srsf7* mutants"). Comparisons were also made between WT mice to show the background noise levels (left half, "Background AS events").(B) Gene Ontology (GO) analysis of the genes that were mis-spliced in *Srsf7* mutant mice. "Up keywords" and "Biological processes" significantly associated with the mis-spliced genes are indicated.(C) Venn diagrams to show overlaps between the ADAS-target genes and the genes mis-spliced in the *Srsf7* mutant.

*Srsf7* Mediates ADAS in *Eif4a2* and *Rbm7* {#sec2.6}
--------------------------------------------

We next sought to describe Srsf7-mediated ADAS in a gene-specific manner. We focused on the *Eif4a2* and *Rbm7* mRNAs, which underwent Srsf7-dependent AS at high significance (Bayes factor \> 10^1/2^). *Eif4a2* underwent ADAS in which exon 11 (E11) was included in the juvenile form and excluded from the adult form throughout the CC, CMs, and Heps ([Figure 6](#fig6){ref-type="fig"}A). Because of a premature stop codon in E11, the juvenile form was shortened and lacked one-third of the C-terminal RNA helicase domain ([Figure 6](#fig6){ref-type="fig"}B), losing two beta-strands and two alpha-helixes of the RNA helicase domain compared with the adult form ([Figure S5](#mmc1){ref-type="supplementary-material"}). However, E11 was skipped in *Srsf7* mutant organs even in juveniles, leading to the expression of the adult form of *Eif4a2* ([Figure 6](#fig6){ref-type="fig"}C). This finding was corroborated by qPCR, which distinguishably measured the two isoforms ([Figure 6](#fig6){ref-type="fig"}D).Figure 6*Srsf7* Mediates ADAS of *Eif4a2* and *Rbm7*(A) *Eif4a2* mRNA expression pattern in the juvenile and adult phases. Exon 11 (E11) is predominantly included in the juvenile phase compared with the adult phase.(B) Schematic of the splicing isoforms of *Eif4a2*. E11 is included in the juvenile isoform and not in the adult isoform. E11 contains the alternative stop codon, thus generating a shorter protein.(C) *Eif4a2* mRNA expression patterns in WT and *Srsf7* mutant organs. E11 is included in WT but not in *Srsf7* mutants. The *Srsf7* mutants thus express the adult form despite the mice being juvenile.(D) qPCR analysis of the *Eif4a2* juvenile and adult isoforms in WT and *Srsf7* mutant mouse tissues (n = 3). Data were normalized to *Tubb5*.(E) *Rbm7* mRNA expression patterns in the juvenile and adult phases. E2 is more frequently included in juveniles than in adults.(F) Schematic of the splicing isoforms of *Rbm7*. E2 is included in the juvenile isoform and not in the adult isoform. E2 contains the alternative stop codon that terminates translation.(G) *Rbm7* mRNA expression pattern in WT and *Srsf7* mutant organs. E2 is included in WT but not in *Srsf7* mutants. The *Srsf7* mutants thus express the adult form despite the mice being juvenile.(H) qPCR analysis of *Rbm7* juvenile and adult isoforms in WT and *Srsf7* mutant mouse tissues (n = 3). Data were normalized to *Tubb5*.Data are represented as the means ± standard deviations. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

*Rbm7*, a gene encoding an RBP associated with snoRNA biogenesis, underwent ADAS in which E2 was included in the juvenile form and excluded from the adult form throughout the CC, CMs, and Heps ([Figure 6](#fig6){ref-type="fig"}E). Because of a stop codon in E2, the juvenile form of *Rbm7* has an open reading frame of 39 amino acids (aa) in length, which is considerably shorter than the adult form, which consists of 265 aa ([Figure 6](#fig6){ref-type="fig"}F). Exon 2 was skipped in *Srsf7* mutant organs even in juveniles, thus yielding the adult form ([Figure 6](#fig6){ref-type="fig"}G). This finding was corroborated by qPCR ([Figure 6](#fig6){ref-type="fig"}H). Thus, our analysis revealed that Srsf7 mediates the ADAS of *Eif4a2* and *Rbm7*, causing switching from juvenile to adult isoforms.

*Srsf7* Is Responsible for ADAS and Establishes the Juvenile Transcriptome {#sec2.7}
--------------------------------------------------------------------------

To assess the regulation of AS by Srsf7 more directly, we established an *in vitro* experimental platform for the analysis of Srsf7-mediated AS. We cloned the genomic sequences of *Eif4a2* and *Rbm7* and constructed minigene plasmids. The AS of *Eif4a2* and *Rbm7* were assessed in the *Srsf7*-KO Neuro2a cell lines ([Figure 7](#fig7){ref-type="fig"}A). The minigene assays revealed that *Srsf7*-KO causes the switching of isoforms from juvenile to adult for both *Eif4a2* ([Figure 7](#fig7){ref-type="fig"}B) and *Rbm7* ([Figure 7](#fig7){ref-type="fig"}C). Furthermore, RNA immunoprecipitation (RIP)-qPCR analysis revealed the binding of *Srsf7* protein to the *Eif4a2* RNA and *Rbm7* RNA ([Figure 7](#fig7){ref-type="fig"}D). These findings indicate that the Srsf7 protein directly mediates the AS of *Eif4a2* and *Rbm7*.Figure 7Srsf7 Mediates Isoform Switching of *Eif4a2* and *Rbm7*(A) Western blot analysis for Srsf7 in WT and *Srsf7*-KO Neuro2a cell lines. Gapdh was analyzed for the loading control.(B) Minigene assay with the *Eif4a2* gene construct. The scheme above shows the plasmid constructed to express exons 10--12 (E10--E12) of mouse *Eif4a2*. The primers used to detect the splicing products are indicated with arrows, and the RT-PCR results are shown below. *Srsf7*-KO induces switching of isoforms from juvenile to adult.(C) Minigene assay with the *Rbm7* gene construct. The scheme above shows the plasmid constructed to express E1--E3 of mouse *Rbm7*. The primers used to detect the splicing products are indicated with arrows, and the RT-PCR results are shown below. *Srsf7*-KO induces switching of isoforms from juvenile to adult.(D) RIP-qPCR was performed in Neuro2a cells after UV-cross-linking followed by immunoprecipitation with the Srsf7 antibody. qPCR was performed for *Eif4a2*, *Rbm7*, and the control, *Rps13*. Fold enrichment was calculated by normalizing to IgG.(E) Schematic describing the role of Srsf7 in ADAS, thus establishing the juvenile transcriptome underlying the anabolic state in juveniles.∗ p \< 0.05, Student\'s t test. Data are represented as the means ± standard deviations.

Thus, Srsf7 mediates the ADAS of the numerous transcripts including *Eif4a2* and *Rbm7*. The influences of *Srsf7* mutation was observed for the splicing of the significant number of genes that were also regulated by ADAS. ADAS enables higher anabolic potentials in juvenile animals through enhancing JAGs and translation-associated genes.

Discussion {#sec3}
==========

The age dependency of AS has not been well elucidated, and implications of ADAS for physiology and pathogenesis remain obscure. Here, we present a comprehensive view of ADAS during postnatal growth in a mouse model. Srsf7 mediates the ADAS of numerous genes including *Eif4a2* and *Rbm7*. Srsf7 contributes to the establishment of the juvenile transcriptome, which is characterized by the expression of JAGs and translation-associated genes, thus underlying the anabolic status of juvenile animals ([Figure 7](#fig7){ref-type="fig"}E).

Although AS has been investigated in terms of tissue- or cell-type specificity, its age dependency has not been comprehensively studied. The juvenile phase is characterized by distinct physiological features, such as growth and maturation, and by distinct gene expression profiles enriched in JAGs ([@bib26]). This ADAS analysis revealed a previously undefined landscape of AS events, unmasking the regulatory layer of gene expression underlying the postnatal growth phase. Our findings indicate that the postnatal growth phase is underlain by splicing-based modifications of the transcriptome, which account for the anabolic status of juvenile animals and the expression of JAGs and translation-associated genes, thus contributing to juvenile properties.

Cellular juvenescence is characterized by the cellular capacities for growth, maturation, differentiation, anabolic metabolism, and resistance to premature senescence ([@bib47]). Cellular juvenescence is lost under suppression of the JALNC Gm14230 ([@bib47]). Here, we showed that Srsf7 depletion also led to a loss of cellular juvenescence, in that cells exhibited impaired growth, differentiation, anabolism, and resistance to premature senescence. As evidenced by experiments in cells and mice, Srsf7 depletion led to decreased phosphorylation of S6, indicating suppressed protein synthesis. Thus, Srsf7 regulates anabolism through protein synthesis both *in vitro* and *in vivo*.

The Srsf7 protein showed nuclear localization, consistent with a splicing function. The nuclear expression of Srsf7 was lost at higher density, zeocin treatment, and RasV12-induced senescence. Srsf7 was not observed to translocate out of the nucleus, suggesting that the Srsf7 protein is regulated by its expression level and not by subcellular localization in the contexts we examined. The cell-density-dependent expression of the Srsf7 protein implied that Srsf7 may control anabolism in response to cell density. Srsf7 expression was also dependent on cellular juvenescence and was lost in RasV12-induced cellular senescence. The genotoxicity of zeocin may induce cell-cycle arrest, and it may also induce loss of cellular juvenescence through the suppression of Srsf7.

The homozygous null mutation of *Srsf7* caused early embryonic lethality, indicating its essentiality in the implantation stage. Homozygous mutations of *Srsf3*, the gene with the greatest similarity to *Srsf7*, cause defects in blastocyst formation before the implantation stage ([@bib28]). This discrepancy demonstrates the non-redundant roles of *Srsf3* and *Srsf7* in blastocyst formation and the implantation stage, respectively.

Although our previous study found that the postnatal growth phase was characterized by age-dependent alteration of the transcriptome, the functional relevance of AS has not been elucidated ([@bib26]). Not only did the juvenile transcriptome undergo extensive genome-wide AS, but we also identified *Srsf7* as a crucial factor for its regulation. *Srsf7* mutation caused erroneous ADAS that resulted in premature loss of JAGs and translation-associated genes. The ADAS events were "fast-forwarded," and premature switching from juvenile to adult isoforms took place. This effect was recapitulated by *in vitro* experiments in Neuro2a cells with null mutations of *Srsf7*, where the juvenile Eif4a2 and Rbm7 isoforms were switched to the adult isoforms prematurely.

We demonstrated that *Eif4a2* and *Rbm7* are direct targets of Srsf7. Srsf7 mediates the inclusion of E11 that contains the alternative stop codon; thus, the juvenile isoform lacks the part of the RNA helicase domain that is crucial for microRNA-mediated translational suppression. Eif4a2 is an ATP-dependent RNA helicase ([@bib25]) that is essential for microRNA-mediated translational repression ([@bib38]). Thus, the shortening of the RNA helicase domain is considered to cause dysregulation of microRNA-mediated translational repression, leading to increased protein expression. microRNA-mediated regulation of growth is also regulated at the level of microRNA biogenesis, which is enhanced by Hippo signaling ([@bib39]). Srsf7-mediated AS of *Eif4a2* may function as a new regulatory layer of microRNA-mediated growth control. Rbm7, together with ZCCHC8 and hMTR4, constitutes the nuclear exosome targeting (NEXT) complex that directs a subset of RNAs, including snoRNA, toward exosomal degradation ([@bib20], [@bib34], [@bib36], [@bib41]). Srsf7 mediates the splicing of the juvenile isoform that includes E2 and a premature stop codon, thus expressing a considerably shorter isoform lacking a part of the RNA recognition motif. The juvenile *Rbm7* isoform spares snoRNAs from degradation, promoting the translation process.

Our findings clarified previously unreported roles for ADAS in the establishment of the juvenile transcriptome and the anabolic status of juvenile animals. Our analysis suggested a more quantitative analysis for AS. Our work implied a possibility that a particular SF may account for the splicing of a portion of a gene transcript and plural SFs contribute to the completion of the splicing of the particular gene. Future works that analyze the contributions of multiple SFs to the particular splicing pattern will clarify how SFs cooperate in the regulation of splicing. Also, in this study, we investigated the AS at the RNA level and not at the proteomic level. Further analysis at the proteomic level will reveal a functional consequence of the RNA splicing on the protein functions. Because AS has numerous implications in pathogenesis, further elucidation of the AS program and the roles of Srsf7 should lead to new therapeutics for intractable diseases, especially of children, in contexts where the juvenile properties and juvenile transcriptome are considered to be compromised. Through the AS, Srsf7 mediates the anabolic functions of the cells. By utilizing the function of Srsf7 to promote anabolism, it might be possible to enhance the growth or regenerative capacity of the organs, for the purpose of treating the intractable diseases without effective treatments or treatment via organ transplantation.

Here, we reported a comprehensive list of ADAS events in the postnatal organs and showed that the splicing of the significant number of ADAS-target genes is mediated by Srsf7. Srsf7 mediates juvenile patterns of AS, thus giving rise to the juvenile transcriptome. Mutation of *Srsf7* causes a premature switch from the juvenile to adult isoforms of at least *Eif4a2* and *Rbm7* both *in vitro* and *in vivo*, resulting in suppressed anabolism and impaired growth. Thus, the Srsf7-mediated ADAS establishes the juvenile transcriptome that underlies juvenile properties.

Limitations of the Study {#sec3.1}
------------------------

•Our AS analysis was performed with a bulk of cells, not single cells. Our analysis implied that different types of AS might occur in a single cell. Future work at the single-cell resolution will reveal how different types of AS occur in transcripts from the same gene.•Our analysis has not determined the comparable contribution of Srsf7 to AS among different SFs. Plural SFs may target to the same gene locus. Future work may make it possible to quantitatively compare the contributions of different SFs.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec3}
==========================

The accession numbers for the high throughput sequencing data reported in this paper are DNA Data Bank of Japan (DDBJ): DRA009510, DRA009537 and DRA009538.

Supplemental Information {#appsec2}
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Document S1. Transparent Methods, Figures S1--S7, and Table S1
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